Does the media prefer GENB or PTGX?

In the previous week, Protagonist Therapeutics had 25 more articles in the media than Generate Biomedicines. MarketBeat recorded 29 mentions for Protagonist Therapeutics and 4 mentions for Generate Biomedicines. Protagonist Therapeutics' average media sentiment score of 1.13 beat Generate Biomedicines' score of 0.35 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protagonist Therapeutics 13 Very Positive mention(s) 8 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GENB or CYTK more profitable?

Generate Biomedicines has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Cytokinetics -1,321.12% N/A -51.01%

Does the media favor GENB or CYTK?

In the previous week, Cytokinetics had 27 more articles in the media than Generate Biomedicines. MarketBeat recorded 31 mentions for Cytokinetics and 4 mentions for Generate Biomedicines. Cytokinetics' average media sentiment score of 0.46 beat Generate Biomedicines' score of 0.35 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 11 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GENB or SYRE more profitable?

Generate Biomedicines' return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Spyre Therapeutics N/A -30.74% -22.23%

Does the media prefer GENB or SYRE?

In the previous week, Spyre Therapeutics had 6 more articles in the media than Generate Biomedicines. MarketBeat recorded 10 mentions for Spyre Therapeutics and 4 mentions for Generate Biomedicines. Spyre Therapeutics' average media sentiment score of 0.37 beat Generate Biomedicines' score of 0.35 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PCVX or GENB more profitable?

Generate Biomedicines' return on equity of 0.00% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Generate Biomedicines N/A N/A N/A

Does the media favor PCVX or GENB?

In the previous week, Vaxcyte had 8 more articles in the media than Generate Biomedicines. MarketBeat recorded 12 mentions for Vaxcyte and 4 mentions for Generate Biomedicines. Vaxcyte's average media sentiment score of 1.10 beat Generate Biomedicines' score of 0.35 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GENB or IMVT more profitable?

Generate Biomedicines' return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Immunovant N/A -69.59% -62.49%

Does the media favor GENB or IMVT?

In the previous week, Immunovant had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 5 mentions for Immunovant and 4 mentions for Generate Biomedicines. Immunovant's average media sentiment score of 0.98 beat Generate Biomedicines' score of 0.35 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Generate Biomedicines (GENB) Competitors

$16.34 +0.06 (+0.37%)

As of 04:00 PM Eastern

Compare

GENB vs. PTGX, CYTK, SYRE, PCVX, and IMVT

Should you buy Generate Biomedicines stock or one of its competitors? Generate Biomedicines's main competitors and comparable companies include Protagonist Therapeutics (PTGX), Cytokinetics (CYTK), Spyre Therapeutics (SYRE), Vaxcyte (PCVX), and Immunovant (IMVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Generate Biomedicines compare to Protagonist Therapeutics?

Generate Biomedicines (NASDAQ:GENB) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, Protagonist Therapeutics had 25 more articles in the media than Generate Biomedicines. MarketBeat recorded 29 mentions for Protagonist Therapeutics and 4 mentions for Generate Biomedicines. Protagonist Therapeutics' average media sentiment score of 1.13 beat Generate Biomedicines' score of 0.35 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protagonist Therapeutics	13 Very Positive mention(s)	8 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Generate Biomedicines presently has a consensus price target of $26.40, suggesting a potential upside of 61.57%. Protagonist Therapeutics has a consensus price target of $147.13, suggesting a potential downside of 1.12%. Given Generate Biomedicines' higher possible upside, equities research analysts clearly believe Generate Biomedicines is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89

Protagonist Therapeutics has a net margin of 29.40% compared to Generate Biomedicines' net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Generate Biomedicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Protagonist Therapeutics	29.40%	12.03%	11.23%

Protagonist Therapeutics has higher revenue and earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$26.48M	79.19	-$203.15M	-$1.59	N/A
Protagonist Therapeutics	$46.02M	209.23	-$130.15M	$1.03	144.47

Summary

Protagonist Therapeutics beats Generate Biomedicines on 14 of the 15 factors compared between the two stocks.

How does Generate Biomedicines compare to Cytokinetics?

Generate Biomedicines (NASDAQ:GENB) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Generate Biomedicines has higher earnings, but lower revenue than Cytokinetics. Generate Biomedicines is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$26.48M	79.19	-$203.15M	-$1.59	N/A
Cytokinetics	$88.04M	104.52	-$784.96M	-$7.22	N/A

Generate Biomedicines currently has a consensus target price of $26.40, indicating a potential upside of 61.57%. Cytokinetics has a consensus target price of $103.37, indicating a potential upside of 39.78%. Given Generate Biomedicines' higher possible upside, analysts clearly believe Generate Biomedicines is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, Cytokinetics had 27 more articles in the media than Generate Biomedicines. MarketBeat recorded 31 mentions for Cytokinetics and 4 mentions for Generate Biomedicines. Cytokinetics' average media sentiment score of 0.46 beat Generate Biomedicines' score of 0.35 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	11 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Cytokinetics	-1,321.12%	N/A	-51.01%

Summary

Cytokinetics beats Generate Biomedicines on 7 of the 12 factors compared between the two stocks.

How does Generate Biomedicines compare to Spyre Therapeutics?

Generate Biomedicines (NASDAQ:GENB) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Generate Biomedicines' return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Spyre Therapeutics	N/A	-30.74%	-22.23%

Generate Biomedicines currently has a consensus target price of $26.40, suggesting a potential upside of 61.57%. Spyre Therapeutics has a consensus target price of $109.69, suggesting a potential upside of 25.72%. Given Generate Biomedicines' higher probable upside, equities research analysts plainly believe Generate Biomedicines is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Spyre Therapeutics has lower revenue, but higher earnings than Generate Biomedicines. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$26.48M	79.19	-$203.15M	-$1.59	N/A
Spyre Therapeutics	$890K	8,621.08	-$155.20M	-$1.95	N/A

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Spyre Therapeutics had 6 more articles in the media than Generate Biomedicines. MarketBeat recorded 10 mentions for Spyre Therapeutics and 4 mentions for Generate Biomedicines. Spyre Therapeutics' average media sentiment score of 0.37 beat Generate Biomedicines' score of 0.35 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spyre Therapeutics beats Generate Biomedicines on 9 of the 15 factors compared between the two stocks.

How does Generate Biomedicines compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Generate Biomedicines (NASDAQ:GENB) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Generate Biomedicines' return on equity of 0.00% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Generate Biomedicines	N/A	N/A	N/A

Generate Biomedicines has higher revenue and earnings than Vaxcyte. Generate Biomedicines is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Generate Biomedicines	$26.48M	79.19	-$203.15M	-$1.59	N/A

96.8% of Vaxcyte shares are held by institutional investors. 3.3% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Vaxcyte had 8 more articles in the media than Generate Biomedicines. MarketBeat recorded 12 mentions for Vaxcyte and 4 mentions for Generate Biomedicines. Vaxcyte's average media sentiment score of 1.10 beat Generate Biomedicines' score of 0.35 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaxcyte currently has a consensus price target of $86.00, indicating a potential upside of 40.59%. Generate Biomedicines has a consensus price target of $26.40, indicating a potential upside of 61.57%. Given Generate Biomedicines' stronger consensus rating and higher possible upside, analysts clearly believe Generate Biomedicines is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Generate Biomedicines beats Vaxcyte on 8 of the 13 factors compared between the two stocks.

How does Generate Biomedicines compare to Immunovant?

Generate Biomedicines (NASDAQ:GENB) and Immunovant (NASDAQ:IMVT) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

47.1% of Immunovant shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Generate Biomedicines has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Generate Biomedicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$26.48M	79.19	-$203.15M	-$1.59	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Generate Biomedicines' return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Immunovant	N/A	-69.59%	-62.49%

Generate Biomedicines presently has a consensus price target of $26.40, suggesting a potential upside of 61.57%. Immunovant has a consensus price target of $44.00, suggesting a potential upside of 12.47%. Given Generate Biomedicines' stronger consensus rating and higher probable upside, research analysts plainly believe Generate Biomedicines is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

In the previous week, Immunovant had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 5 mentions for Immunovant and 4 mentions for Generate Biomedicines. Immunovant's average media sentiment score of 0.98 beat Generate Biomedicines' score of 0.35 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Generate Biomedicines beats Immunovant on 8 of the 13 factors compared between the two stocks.

Get Generate Biomedicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GENB vs. The Competition

Export

Metric	Generate Biomedicines	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.10B	$4.02B	$7.25B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	-10.28	12.72	273.59	25.44
Price / Sales	79.19	1,361.39	675.80	123.63
Price / Cash	N/A	105.29	76.98	52.08
Price / Book	4.60	16.29	12.89	6.14
Net Income	-$203.15M	-$22.72M	$3.47B	$349.01M
7 Day Performance	3.61%	-1.37%	-0.32%	-1.47%
1 Month Performance	13.95%	11.08%	6.52%	2.47%
1 Year Performance	N/A	53.72%	25.19%	15.84%

Generate Biomedicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GENB Generate Biomedicines	2.356 of 5 stars	$16.34 +0.4%	$26.40 +61.6%	N/A	$2.10B	$26.48M	N/A	312
PTGX Protagonist Therapeutics	1.5437 of 5 stars	$151.16 -2.3%	$140.53 -7.0%	+148.2%	$9.81B	$46.02M	147.16	120	Trending News Analyst Forecast Analyst Revision
CYTK Cytokinetics	2.85 of 5 stars	$77.72 +0.8%	$102.20 +31.5%	+45.0%	$9.65B	$88.04M	N/A	250	Analyst Forecast Insider Trade Gap Up
SYRE Spyre Therapeutics	2.5691 of 5 stars	$107.20 +0.5%	$111.69 +4.2%	+423.5%	$9.43B	$890K	N/A	73	Analyst Forecast Gap Down
PCVX Vaxcyte	2.3877 of 5 stars	$61.21 -1.1%	$86.00 +40.5%	+95.1%	$9.12B	N/A	N/A	160	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GENB) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Generate Biomedicines (GENB) Competitors

GENB vs. PTGX, CYTK, SYRE, PCVX, and IMVT

How does Generate Biomedicines compare to Protagonist Therapeutics?

Summary

How does Generate Biomedicines compare to Cytokinetics?

Summary

How does Generate Biomedicines compare to Spyre Therapeutics?

Summary

How does Generate Biomedicines compare to Vaxcyte?

Summary

How does Generate Biomedicines compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Generate Biomedicines (GENB) Competitors

GENB vs. PTGX, CYTK, SYRE, PCVX, and IMVT

How does Generate Biomedicines compare to Protagonist Therapeutics?

Does the media prefer GENB or PTGX?

Do insiders & institutionals hold more shares of GENB or PTGX?

Do analysts prefer GENB or PTGX?

Is GENB or PTGX more profitable?

Which has preferable valuation & earnings, GENB or PTGX?

Summary

How does Generate Biomedicines compare to Cytokinetics?

Which has better valuation and earnings, GENB or CYTK?

Do analysts rate GENB or CYTK?

Does the media favor GENB or CYTK?

Is GENB or CYTK more profitable?

Summary

How does Generate Biomedicines compare to Spyre Therapeutics?

Is GENB or SYRE more profitable?

Do analysts recommend GENB or SYRE?

Which has stronger earnings & valuation, GENB or SYRE?

Do insiders & institutionals hold more shares of GENB or SYRE?

Does the media prefer GENB or SYRE?

Summary

How does Generate Biomedicines compare to Vaxcyte?

Is PCVX or GENB more profitable?

Which has preferable valuation & earnings, PCVX or GENB?

Do insiders & institutionals have more ownership in PCVX or GENB?

Does the media favor PCVX or GENB?

Do analysts recommend PCVX or GENB?

Summary

How does Generate Biomedicines compare to Immunovant?

Do institutionals & insiders hold more shares of GENB or IMVT?

Which has preferable earnings & valuation, GENB or IMVT?

Is GENB or IMVT more profitable?

Do analysts prefer GENB or IMVT?

Does the media favor GENB or IMVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GENB vs. The Competition

Generate Biomedicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools